<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33491">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948219</url>
  </required_header>
  <id_info>
    <org_study_id>LA-01-PEC-1</org_study_id>
    <nct_id>NCT01948219</nct_id>
  </id_info>
  <brief_title>ENTegral Clinical Trial</brief_title>
  <official_title>An Evaluation of the ENTegral Artificial Larynx (AL) in Patients Indicated for Total Laryngectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ProTiP Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ProTiP Medical</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to evaluate the feasibility, safety and efficacy of
      the ENTegral Artificial Larynx (AL) in patients indicated for total laryngectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility of device implant procedure</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse event associated with device implantation procedure</description>
  </primary_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>1, 3, 6 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life using EORTC QLQ-C30 and QLQ-H&amp;N25 questionnaires</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of patients with adverse events will be assessed at each follow-up during the 1 year patient follow-up</description>
  </other_outcome>
  <other_outcome>
    <measure>Dyspnea evolution</measure>
    <time_frame>1,2,3,6,9 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Dyspnea evaluation using the Heyse-Moore scale at 1, 2, 3, 6, 9 months and 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Phonation evolution</measure>
    <time_frame>1,2,3,6,9 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient phonation (able to talk and be understood, whispered voice) will be assessed at 1, 2, 3, 6, 9 months and 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Implant use</measure>
    <time_frame>1,2,3,6,9 months and 1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Implant use (manual closure of the tracheostomy orifice) duration will be assessed at 1, 2, 3, 6, 9 months and 1 year, allowing eventually to surgically close the orifice</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Total Laryngectomy</condition>
  <arm_group>
    <arm_group_label>ENTegral Artificial Larynx implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ENTegral Artificial Larynx implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ENTegral Artificial Larynx implant</intervention_name>
    <arm_group_label>ENTegral Artificial Larynx implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age more than or equal to 18 years old

          -  Is indicated for total laryngectomy (first intention)

          -  Must be able to comply with study requirements

          -  Must be able to understand and be willing to provide written informed consent

        Exclusion Criteria:

          -  Any condition that precludes the implantation of the ENTegral AL

          -  Existing coagulation disorder

          -  Contraindication for general anesthesia

          -  Tumoral extension outside of the larynx invading through extra-laryngeal structures

          -  Previous radiotherapy

          -  Life-expectancy &lt; 12 months

          -  Be pregnant of breastfeeding or intention to becoming pregnant during study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Audrey Maniette</last_name>
    <email>a.maniette@protipmedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie Henry</last_name>
    <email>sophiehenryconsulting@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Lawson, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 18, 2013</lastchanged_date>
  <firstreceived_date>September 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
